BCL2 and acute myeloid leukemia: Additionally, Bcl-2 inhibitor venetoclax has become the standard of care in combination with hypomethylating agents for newly diagnosed AML in unfit patients and 10 d decitabine monotherapy is seldom utilized [22,23,24].